“At the moment, these results seem to be quite reassuring for most people with MS,” Marco Salvetti, MD, PhD, professor at Sapienza University and Sant’Andrea Hospital, in Rome, said in a press release.
Nevertheless, the early nature of these data must be taken into account. Evidence is also still lacking to determine how the use of disease-modifying therapies (DMTs), sex, or simultaneous conditions (comorbidities) affect this patient population, the researchers noted.
Their study, “An Italian programme for COVID-19 infection in multiple sclerosis,” was published in the journal The Lancet Neurology. It was written by Maria Pia Sormani, PhD, on behalf of the Italian Study Group on COVID-19 infection in MS.
Findings come from the pilot phase of an international web platform, called MuSC-19 (Multiple Sclerosis and COVID-19), that is collecting clinical and demographic data, as well as information on DMTs, on MS patients who have symptoms and signs of COVID-19 regardless of a confirmed infection via nasal and pharyngeal swabs.
The platform, donated by Roche, became active on March 14 in Italy, among the first European countries to experience severely the effects of COVID-19. Data are collected via an electronic case report form specifically developed for this pandemic, and provided to healthcare providers.
MuSC-19 is part of a program developed by The Italian Multiple Sclerosis Society (AISM), its Foundation (FISM), and the Multiple Sclerosis Study Group of the Italian Society of Neurology. The platform is also linked to the Italian MS Register, which currently collects data on more than 60,000 people with MS in Italy.
MuSC-19’s goal is to better understand the relationship between MS and COVID-19 and how a number of factors — namely age, sex, comorbidities, and treatments — affect infection outcomes in MS patients.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?